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Commentary Hypoxia-specific targets in cancer therapy: role of 
splice variants
Dirk Vordermark
Abstract
Tumour hypoxia is a well known adverse prognostic factor in the treatment of solid tumours. Hypoxia-inducible factor 
1α (HIF-1α), a transcription factor subunit regulating a large number of hypoxia-responsive genes, is considered an 
attractive target for novel treatment approaches, due to a frequently reported association between HIF-1α 
overexpression and poor outcome in clinical series. This month in BMC Medicine, Dales et al. report on splice variants of 
HIF-1α in fresh frozen tissue samples of early human breast cancer, finding an association of mRNA levels of the variant 
HIF-1αTAG with adverse clinical factors (lymph node status, hormone receptor status) and poor metastasis-free survival. 
This preliminary study addresses the possibility that specific targeting of individual isoforms resulting from alternative 
splicing may play a role in HIF-1-directed treatment approaches.
See research article: http://www.biomedcentral.com/1741-7015/8/44
Background
This month in BMC Medicine, Dales and coworkers
report on the expression of hypoxia-inducible factor 1α
(HIF-1α) splice variants in human breast cancer [1]. This
work represents an early and preliminary investigation
that may become part of a process leading to further indi-
vidualisation of cancer therapy, specifically addressing
the role of hypoxic tumour cells.
Discussion
Low oxygenation of tumour cells is a well known adverse
prognostic factor in cancer treatment. It occurs due to (a)
rapid tumour growth with resulting long diffusion dis-
tances from the nearest blood vessel ('diffusion-limited
hypoxia'), as well as (b) the chaotic structure of pathologi-
cal tumour vessels and resulting inadequate perfusion in
part of these vessels ('perfusion-limited hypoxia') [2]. It
was established mainly in the 1990 s that a low pretreat-
ment intratumoural partial oxygen pressure (pO2), as
determined by needle electrode measurement, is associ-
ated with a poor outcome of treatment, in particular
radiotherapy but also surgical treatment, of cervical can-
cer or head and neck cancer [3,4]. This association has
been explained by the reduced ability of ionizing radia-
tion to produce DNA damage in the absence of oxygen as
well as, more recently, by an increased potential of
hypoxic tumour cells for proliferation, invasion, metasta-
sis and angiogenesis [2].
For decades, investigators have attempted to overcome
the treatment resistance of hypoxic tumours in clinical
trials, for example by adding so-called 'hypoxic radiosen-
sitiser' drugs to the regimens or introducing hyperbaric
oxygen. Although many of the individual trials were nega-
tive, a modern meta-analysis confirms the efficacy of
hypoxia-directed treatments [5]. While previous strate-
gies were directed at all patients with a given tumour
diagnosis, more modern approaches combine (a) the
selection of patients with particularly hypoxic tumours
and (b) the addition of hypoxia-specific treatment modal-
ities to standard radiotherapy/chemotherapy only in
these subgroups.
Determining tumour oxygenation by needle electrode
measurements has not been fully accepted in clinical
practice and less invasive methods have been proposed:
These include the immunohistochemical detection of
'exogenous hypoxia markers' (2-nitroimidazole deriva-
tives such as pimonidazole) injected intraveneously
before a biopsy, the imaging of hypoxic tumour areas by
nuclear medicine methods (for example, F-misonidazole
positron emission tomography) or even the measurement
of proposed secreted hypoxia markers (for example,
osteopontin) in the patient plasma [6-8].
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The transcription factor HIF-1 is a central regulator of
the physiological or pathophysiological response of mam-
malian cells to low oxygen levels and has so far been
described to regulate hundreds of genes in a hypoxia-
dependent manner, many of which are growth factors or
involved in cell proliferation, metabolism or vessel forma-
tion [9]. HIF-1 is a heterodimer consisting of one of the
two α subunits (HIF-1α or HIF-2α) and HIF-1β. Under
hypoxic conditions, the oxygen-sensitive subunit HIF-1α
is not degraded via ubiquitylation but rather stabilises,
translocates to the nucleus, heterodimerises with consti-
tutively expressed HIF-1β and binds, in the presence of
cofactors, to the hypoxia-responsive elements of HIF-1-
regulated genes. HIF-1 is thus assumed to be regulated
mostly by protein degradation.
HIF-1α protein itself and HIF-1-regulated proteins, for
example, carbonic anhydrase IX (CA IX) have been stud-
ied by immunohistochemistry in paraffin-embedded
tumour material as potential 'endogenous hypoxia mark-
ers'. Due to the availability of such material, a large num-
b e r  o f  r e t r o s p e c t i v e  a n a l y s e s  o f  s e r i e s  w i t h  l o n g - t e r m
clinical outcome were published and, despite some con-
cern about the reproducibility of HIF-1α staining, signifi-
cant associations between a strong expression of such
HIF-1-related proteins and poor prognosis was seen in
the majority of studies on a wide range of solid tumour
entities [10]. Such observations were also made in breast
cancer [11,12], the topic now studied by Dales et al.
Despite its negative prognostic relevance, tumour
hypoxia has also been discussed as an opportunity for
tumour-specific treatment approaches, for low pO2 levels
as found in solid tumours very rarely occur in normal tis-
sues [13]. Therefore, a prognostically and mechanistically
relevant gene or gene product such as HIF-1α or down-
stream genes may serve at the same time as an indicator
of hypoxic treatment resistance (and therefore be used
for patient selection) and as a therapeutic target (in a
group thus selected). Inhibitors of the HIF-1 pathway
have been grouped into inhibitors of transcription (for
example, topoisomerase 2 inhibitors), inhibitors of trans-
lation (for example, topotecan, taxanes, epidermal
growth factor receptor (EGFR)-targeting agents), inhibi-
tors of DNA binding and transactivation (for example,
chetomin) and promoters of degradation (for example,
farnesyl transferase inhibitors) [14]. HIF-1 inhibitors
have been shown in vitro and in vivo to reduce angiogen-
esis and tumour growth and enhance radiosensitivity [15-
18]. Several HIF-1 inhibitors are now in early clinical tri-
als.
The findings published by Dales et al. [1] are interesting
for the further development of HIF-1 targeting
approaches. The authors describe the presence of differ-
ent HIF-1α splice variants in human breast cancer and
non-malignant tissue samples. Splice variants result from
alternative splicing, a process by which the exons of the
RNA produced by transcription of a primary gene are
reconnected in multiple ways, resulting in different
mRNAs which may be translated into different protein
isoforms. By performing real-time quantitative PCR of
fresh frozen tissue, the authors demonstrate that the
m R N A  l e v e l s  o f  a  s p e c i f i c  s p l i c e  v a r i a n t  t e r m e d  H I F -
1αTAG  a r e  a s s o c i a t e d  w i t h  p o s i t i v e  l y m p h  n o d e  s t a t u s ,
high tumour grade and negative oestrogen and progester-
one status, as well as poor metastasis-free survival (on
univariate analysis) in early breast cancer.
Although this study has a number of limitations (small
sample size, limited information on patient and treatment
characteristics, selection of two subgroups with good and
poor metastasis-free survival rather than a homogenous
cohort) and failed to demonstrate an independent prog-
nostic role (on multivariate analysis) of HIF-1α splice
variant expression, follow-up studies may advance our
understanding of the role of alternative splicing in the
identification of prognostic variables and therapeutic tar-
gets. In in vitro tumour models, small interfering RNAs
(siRNAs) directed against wild-type vs individual splice
variants of genes relevant for treatment resistance have
produced specific effects on clonogenicity and radiosen-
sitivity of human tumour cells [19].
Conclusions
The data from Dales et al. suggest that if splice variants
detectable in clinical tumour samples can reliably be
related to clinical endpoints, targeting approaches
directed specifically at these variants may play a role in
the further individualisation of cancer treatment.
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